Microfluidic Apparatus With Sealed Paths for mRNA Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies for manufacturing and formulating polynucleotide therapeutics, particularly mRNA therapeutics, face issues of contamination, degradation, high costs, and inefficiencies in centralized production, which are not suitable for point-of-care applications.
Innovation Solution
The development of microfluidic apparatuses and devices that operate in a closed path, utilizing a seating mount, fluid vials, fluidic lines, and controllers to drive fluidic movement, enabling the synthesis, purification, and formulation of therapeutic polynucleotides, such as mRNA, in a controlled and sealed environment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If centralized production is used for polynucleotide therapeutics, then manufacturing capability is improved, but cost and contamination risk increase
Solution Approach 1:
The system divides the manufacturing process into discrete, isolated microfluidic chambers and fluidic pathways. Each reaction step occurs in separate compartments that can be independently controlled and sealed, preventing cross-contamination while maintaining manufacturing capability through modular architecture.
Solution Approach 2:
The microfluidic system maintains closed, sealed fluidic pathways that create controlled inert environments for the therapeutic polynucleotides. The closed-loop design with sealed connectors and integrated fluidic circuits prevents exposure to environmental contaminants while enabling centralized production scalability.
2Productivity
If centralized production is used for polynucleotide therapeutics, then manufacturing capability is improved, but production time and cost increase
Solution Approach 1:
The system pre-configures all fluidic pathways, reagent delivery systems, and processing chambers before the therapeutic production begins. Reagents are pre-loaded into the microfluidic device, and all necessary components are assembled in advance, enabling rapid initiation of the manufacturing process without time-consuming setup steps during production.
Solution Approach 2:
The microfluidic system enables continuous, automated fluidic movement through sealed pathways, eliminating idle time between steps. The integrated pump and valve system maintains continuous processing flow, and the closed-loop design allows immediate sequential execution of multiple operations without interruption or manual intervention delays.
3Ease of operation
If open fluid paths are used, then ease of operation is improved, but contamination and degradation increase
Solution Approach 1:
The system employs sealed fluidic connectors, integrated microfluidic channels, and automated pumping systems as intermediaries between fluid reservoirs and reaction chambers. These controlled interfaces maintain sealed pathways while enabling precise fluid delivery, eliminating the need for open connections that would expose the therapeutic to contamination.
Solution Approach 2:
The system replaces manual fluid handling and open mechanical connections with an integrated automated microfluidic system. The closed-loop design uses built-in pumps, valves, and pressure-driven flow control to manage fluid movement, eliminating the need for open fluid paths and manual operations that would compromise sterility and lead to degradation.
4Productivity
If scalable manufacturing is implemented, then productivity is improved, but manufacturing complexity increases
Solution Approach 1:
The microfluidic device incorporates multi-functional integrated components that perform multiple operations within a single platform. The same device can conduct synthesis, purification, and formulation steps using identical sealed fluidic pathways and control systems, enabling scalability without proportionally increasing complexity through component proliferation.
Solution Approach 2:
The system merges multiple manufacturing functions into a single integrated microfluidic platform. Fluidic pathways are combined for multiple operations, control systems are unified, and the closed-loop architecture consolidates what would otherwise require separate equipment. This integration enables scalable production while managing complexity through consolidation rather than multiplication of components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These apparatuses provide a cost-effective, scalable, and contamination-free method for producing therapeutic polynucleotides, suitable for point-of-care use, by ensuring sealed fluid paths and precise control over fluidic movements and reactions.
Implementation Method 1
a controller configured to control the application of pressure through the pressure lines to drive fluidic movement in the microfluidic path device
Implementation Method 2
each fluidic line and each pressure line is configured to be biased against the microfluidic path device seated in the seating mount
Data Source
AI summary
Apparatuses and methods are described herein for processing polynucleotides in a sealed path environment. The apparatuses include optical sensors to monitor operations and to track material usage for good manufacturing practice.